ESMO 2023 | 7-y results from CheckMate 238: adjuvant NIVO vs IPI in resected stage III/IV melanoma

Paolo Ascierto, MD, Istituto Tumori Fondazione Pascale, Naples, Italy, presents 7-year results from the Phase III CheckMate 238 (NCT02388906) trial. At 5 years, CheckMate 238 revealed sustained superiority of nivolumab over ipilimumab in recurrence-free survival (RFS) for high-risk resected melanoma. At 7 years, nivolumab continued to show superior RFS, distant metastasis-free survival (DMFS), and progression-free survival through next-line therapy (PFS2), with fewer recurrence events and deaths compared to ipilimumab. Subsequent systemic therapy was less frequent with nivolumab. The data support nivolumab’s long-term efficacy, emphasizing the need for extended imaging and follow-up beyond 5 years. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.